[50]
In particular, Novopharm says that Prothonotary Milczynski was clearly wrong when she accepted the evidence of Dr. Liston with respect to the effect of an NOA on the confidentiality of documents in the possession of Health Canada. This evidence was to the effect that, in Dr. Liston's opinion, the delivery of an NOA "... breaches or contravenes the concept of confidentiality." Dr. Liston does not speak for Health Canada (which he admitted) and ceased working for Health Canada before the
Regulations
came into force (and therefore before the first NOA was ever served.) His evidence is in direct contrast to that of Mr. Windross, who clearly stated that Health Canada keeps materials in an ANDS confidential until a product goes to market, which is well after the delivery of an NOA and after the issuance of an NOC.